Agile Therapeutics, Inc. (AGRX)
Aug 26, 2024 - AGRX was delisted (reason: acquired by Insud Pharma)
1.510
0.00 (0.00%)
Inactive · Last trade price on Aug 26, 2024

Agile Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020Q2 2020Q1 2020Q4 2019Q3 2019
Period Ending
Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21 Jun '21 Mar '21 Dec '20 Sep '20 Jun '20 Mar '20 Dec '19 Sep '19
5.585.723.616.665.53.81432.131.761.511.291.190.120.75-----
Revenue Growth (YoY)
1.33%49.91%-9.56%121.92%158.84%116.52%163.94%133.26%79.41%1418.10%102.14%---------
Cost of Revenue
1.51.682.192.482.3121.651.432.231.535.72.711.151.160.28-----
Gross Profit
4.084.041.424.183.21.812.341.58-0.110.23-4.19-1.420.04-1.050.47-----
Selling, General & Admin
6.296.35.427.487.627.768.878.3810.4414.5516.4912.7615.8313.0514.210.996.384.453.272.14
Research & Development
0.540.50.050.710.70.760.350.790.861.261.681.590.862.123.013.663.663.162.842.36
Operating Expenses
6.836.795.488.198.328.529.229.1611.2915.8118.1714.3516.6915.1817.2114.6610.047.626.114.5
Operating Income
-2.75-2.76-4.05-4-5.13-6.71-6.88-7.59-11.4-15.57-22.36-15.77-16.65-16.22-16.74-14.66-10.04-7.62-6.11-4.5
Interest Expense
--0.19-0.31-0.34-0.37-0.4-0.43-1-0.82-0.87-1-1-0.99-0.92-0.9-0.91-0.9-0.4--
Interest & Investment Income
0.030.020.020.010.020.030.030.0500000.010.020.030.040.120.130.080.07
Other Non Operating Income (Expenses)
-9.154.2-0.133.531.671.693.3513.747.051.383.83---------
EBT Excluding Unusual Items
-11.871.28-4.47-0.8-3.81-5.39-3.935.19-5.17-15.06-19.53-16.77-17.64-17.13-17.62-15.52-10.83-7.88-6.02-4.43
Gain (Loss) on Sale of Assets
--------11.12------------
Pretax Income
-11.871.28-4.47-0.8-3.81-5.39-3.93-5.93-5.17-15.06-19.53-16.77-17.64-17.13-17.62-15.52-10.83-7.88-6.02-4.43
Income Tax Expense
----------4.68----------
Net Income
-11.871.28-4.47-0.8-3.81-5.39-3.93-5.93-5.17-10.39-19.53-16.77-17.64-17.13-17.62-15.52-10.83-7.88-6.02-4.43
Net Income to Common
-11.871.28-4.47-0.8-3.81-5.39-3.93-5.93-5.17-10.39-19.53-16.77-17.64-17.13-17.62-15.52-10.83-7.88-6.02-4.43
Net Income Growth (YoY)
--------------------
Shares Outstanding (Basic)
75332111000000000000
Shares Outstanding (Diluted)
75332111000000000000
Shares Change (YoY)
287.40%407.86%259.38%298.69%1862.00%1363.86%1298.69%1478.44%103.40%42.20%34.84%7.34%1.69%14.32%39.78%62.94%99.25%105.46%81.98%55.94%
EPS (Basic)
-1.730.28-1.51-0.27-2.15-5.91-4.77-8.01-57.29-166.68-331.25-357.77-397.70-390.93-402.98-355.44-248.24-205.68-192.49-165.34
EPS (Diluted)
-1.730.28-1.51-0.27-2.15-5.91-4.77-8.01-57.29-166.68-331.25-357.77-397.70-390.93-402.98-360.00-248.24-205.68-192.49-165.34
EPS Growth (YoY)
--------------------

Additional Metrics

Fiscal Quarter
Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020Q2 2020Q1 2020Q4 2019Q3 2019
Period Ending
Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21 Jun '21 Mar '21 Dec '20 Sep '20 Jun '20 Mar '20 Dec '19 Sep '19
Free Cash Flow
0.23-2.480.170.37-8.52-1.6-1.56-16.7-2.94-14.88-16.67-18.65-15.41-14.74-17.4-15.39-6.82-8.05-3.34-5.11
Free Cash Flow Per Share
0.03-0.530.060.12-4.81-1.75-1.89-22.57-32.60-238.78-282.79-397.73-347.58-336.41-397.93-352.47-156.45-209.99-106.71-190.64
Gross Margin
73.17%70.61%39.37%62.82%58.08%47.47%58.63%52.53%-4.94%13.29%-276.55%-110.64%3.38%-62.35%-----
Operating Margin
-49.25%-48.23%-112.12%-60.04%-93.15%-175.92%-172.12%-252.70%-536.12%-884.33%-1476.75%-1225.64%-1405.15%-13984.48%-2235.11%-----
Profit Margin
-212.91%22.46%-123.69%-11.99%-69.22%-141.36%-98.37%-197.53%-243.09%-589.72%-1289.96%-1303.19%-1488.35%-14765.52%-2352.47%-----
Free Cash Flow Margin
4.18%-43.32%4.76%5.48%-154.81%-41.83%-39.01%-556.40%-138.33%-844.80%-1101.25%-1448.72%-1300.76%-12706.03%-2322.96%-----
EBITDA
-2.64-2.65-3.95-3.9-5.03-6.62-6.79-7.32-10.81-14.99-21.78-15.22-16.1-15.68-16.61-14.6-9.99-7.57-6.06-4.46
EBITDA Margin
-47.42%-46.43%-109.35%-58.57%-91.42%-173.49%-169.84%-243.97%------------
D&A For EBITDA
0.10.10.10.10.10.090.090.260.590.590.580.550.550.550.130.060.050.040.040.04
EBIT
-2.75-2.76-4.05-4-5.13-6.71-6.88-7.59-11.4-15.57-22.36-15.77-16.65-16.22-16.74-14.66-10.04-7.62-6.11-4.5
EBIT Margin
-49.25%-48.23%-112.12%-60.04%-93.15%-175.92%-172.12%-252.70%------------
Advertising Expenses
-------0.91.93.3-2.733.1------
SEC Filings: 10-K · 10-Q